All Data
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Adjuvanted recombinant protein-based COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: GlaxoSmithKline
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
In a phase I/II study of Sanofi/GSK’s adjuvanted recombinant protein-based vaccine, interim results found the vaccine induced an immune response comparable to recovered COVID-19 patients in adults aged 18 to 49 years.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Adjuvanted COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Gavi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 28, 2020
Details:
Sanofi and GSK intend to make available 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine, if approved by regulatory authorities and subject to contract, to the COVAX Facility.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Adjuvanted COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: European Union
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 18, 2020
Details:
Agreement supports scale-up of manufacturing capabilities in several European countries . The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): Adjuvanted COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: GlaxoSmithKline
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020
Details:
The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: U.S Department of Health and Human Services
Deal Size: $2,100.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration July 31, 2020
Details:
Collaborating with the U.S. Department of Health and Human Services and Department of Defense will help fund the development activities and secure scale-up of Sanofi’s and GSK’s manufacturing capabilities in the U.S for the recombinant protein-based, adjuvanted vaccine.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: European Union
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 31, 2020
Details:
The vaccine candidate developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology.
Sanofi Active Ingredient Solutions cover both APIs sales & CDMO.
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: UK government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 29, 2020
Details:
The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant technology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VLA2001,CpG 1018
Therapeutic Area: Infections and Infectious Diseases Product Name: VLA2001
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2020
Details:
VLA2001 leverages the manufacturing platform of Valneva’s licensed Japanese encephalitis vaccine, IXIARO® and is the first publicly announced inactivated vaccine against COVID-19 to commence clinical development in Europe.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
